407 related articles for article (PubMed ID: 29383686)
21. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
22. Development of immunotherapy for brain metastasis (Review).
Ding R; Chen L; Su Z; Xiong T; Wen Q; Peng Q; Jiang F
Int J Oncol; 2020 Sep; 57(3):665-677. PubMed ID: 32705149
[TBL] [Abstract][Full Text] [Related]
23. Management of Brain Metastases in the New Era of Checkpoint Inhibition.
Lauko A; Thapa B; Venur VA; Ahluwalia MS
Curr Neurol Neurosci Rep; 2018 Aug; 18(10):70. PubMed ID: 30121715
[TBL] [Abstract][Full Text] [Related]
24. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment.
El Rassy E; Botticella A; Kattan J; Le Péchoux C; Besse B; Hendriks L
Cancer Treat Rev; 2018 Jul; 68():69-79. PubMed ID: 29883857
[TBL] [Abstract][Full Text] [Related]
25. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy targeting immune check-point(s) in brain metastases.
Di Giacomo AM; Valente M; Covre A; Danielli R; Maio M
Cytokine Growth Factor Rev; 2017 Aug; 36():33-38. PubMed ID: 28736183
[TBL] [Abstract][Full Text] [Related]
28. Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.
Kourie HR; Kanaan H; Awada G; Awada AH
Future Oncol; 2017 May; 13(12):1097-1103. PubMed ID: 28326837
[TBL] [Abstract][Full Text] [Related]
29. The inflammatory microenvironment in brain metastases: potential treatment target?
Berghoff AS; Preusser M
Chin Clin Oncol; 2015 Jun; 4(2):21. PubMed ID: 26112807
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
32. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
[TBL] [Abstract][Full Text] [Related]
33. Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.
Lakin N; Rulach R; Nowicki S; Kurian KM
Front Oncol; 2017; 7():141. PubMed ID: 28730140
[TBL] [Abstract][Full Text] [Related]
34. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
35. Novel immunotherapy in the treatment of advanced non-small cell lung cancer.
Santabarbara G; Maione P; Rossi A; Palazzolo G; Gridelli C
Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1571-1581. PubMed ID: 27623999
[TBL] [Abstract][Full Text] [Related]
36. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
[TBL] [Abstract][Full Text] [Related]
37. The role of systemic therapies in the management of melanoma brain metastases.
Lyle M; Long GV
Curr Opin Oncol; 2014 Mar; 26(2):222-9. PubMed ID: 24434634
[TBL] [Abstract][Full Text] [Related]
38. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
Lee HW
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapy for esophagogastric cancer: immune checkpoint inhibition.
Lyons TG; Ku GY
Chin Clin Oncol; 2017 Oct; 6(5):53. PubMed ID: 29129093
[TBL] [Abstract][Full Text] [Related]
40. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]